CHAMPIONS ONCOLOGY, INC.CSBREarnings & Financial Report
Champions Oncology is an American technology company that develops mouse avatars. Called TumorGrafts, they are used to test a panel of chemotherapy regimens, targeted therapies and monoclonal antibodies to identify potential therapeutic options for cancer patients. The company was founded in 2007 by David Sidransky, M.D., a Johns Hopkins University oncologist.
Revenue
$14.0M
Gross Profit
$6.0M
Operating Profit
$-527.0K
Net Profit
$-436.0K
Gross Margin
42.9%
Operating Margin
-3.8%
Net Margin
-3.1%
YoY Growth
-0.5%
EPS
$-0.03
CHAMPIONS ONCOLOGY, INC. Q1 FY2026 Financial Summary
CHAMPIONS ONCOLOGY, INC. reported revenue of $14.0M (down 0.5% YoY) for Q1 FY2026, with a net profit of $-436.0K (down 133.2% YoY) (-3.1% margin). Cost of goods sold was $8.0M, operating expenses totaled $6.5M.
Key Financial Metrics
| Total Revenue | $14.0M |
|---|---|
| Net Profit | $-436.0K |
| Gross Margin | 42.9% |
| Operating Margin | -3.8% |
| Report Period | Q1 FY2026 |
Revenue Breakdown
CHAMPIONS ONCOLOGY, INC. Q1 FY2026 revenue of $14.0M breaks down across 2 segments, led by Pharmacology Services at $13.2M (94.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Pharmacology Services | $13.2M | 94.5% |
| Other | $765.0K | 5.5% |
CHAMPIONS ONCOLOGY, INC. Revenue by Segment — Quarterly Trend
CHAMPIONS ONCOLOGY, INC. revenue by segment across the last 4 reported quarters, showing how each business line (such as Pharmacology Services and Other) has evolved quarter over quarter.
| Segment | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 |
|---|---|---|---|---|
| Pharmacology Services | $14.5M | $13.2M | $11.3M | $11.7M |
| Other | $520.0K | $765.0K | $1.0M | $869.0K |
CHAMPIONS ONCOLOGY, INC. Annual Revenue by Year
CHAMPIONS ONCOLOGY, INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $56.9M).
| Year | Annual Revenue |
|---|---|
| 2025 | $56.9M |
| 2024 | $50.2M |
| 2023 | $53.9M |
| 2022 | $49.1M |
CHAMPIONS ONCOLOGY, INC. Quarterly Revenue & Net Profit History
CHAMPIONS ONCOLOGY, INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 FY2026 | $15.0M | +11.5% | $268.0K | 1.8% |
| Q1 FY2026 | $14.0M | -0.5% | $-436.0K | -3.1% |
| Q4 FY2025 | $12.4M | -11.8% | $-1.8M | -14.9% |
| Q3 FY2025 | $17.0M | +41.8% | $4.5M | 26.4% |
| Q2 FY2025 | $13.5M | +16.6% | $728.0K | 5.4% |
| Q1 FY2025 | $14.1M | +11.9% | $1.3M | 9.3% |
| Q4 FY2024 | $14.0M | +7.1% | $-109.0K | -0.8% |
| Q3 FY2024 | $12.0M | -5.9% | $-2.5M | -21.1% |
Income Statement
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0M | $14.0M | $14.1M | $13.5M | $17.0M | $12.4M | $14.0M | $15.0M |
| YoY Growth | -5.9% | 7.1% | 11.9% | 16.6% | 41.8% | -11.8% | -0.5% | 11.5% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $26.8M | $26.1M | $24.9M | $25.2M | $30.6M | $32.3M | $30.5M | $30.2M |
| Liabilities | $28.8M | $28.0M | $25.3M | $24.6M | $25.2M | $28.6M | $27.0M | $25.9M |
| Equity | $-2.1M | $-1.9M | $-332000 | $681000 | $5.5M | $3.8M | $3.5M | $4.2M |
Cash Flow
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-919000 | $-1.8M | $311000 | $-283000 | $490000 | $6.9M | $600000 | $-1.7M |